Your browser doesn't support javascript.
loading
Comprehensive exploration of FCHO1 mutations: Clinical manifestations and implications across disorders.
Alomari, Omar; Ertan, Sinem Nur; Mokresh, Muhammed Edib; Yazicilar, Elif; Pourali, Maryam; Akyokus, Fatma Esra; Sager, Safiye Gunes; Cag, Yakup.
Afiliación
  • Alomari O; Hamidiye International School of Medicine, University of Health Sciences, Istanbul, Turkey.
  • Ertan SN; Hamidiye International School of Medicine, University of Health Sciences, Istanbul, Turkey.
  • Mokresh ME; Hamidiye International School of Medicine, University of Health Sciences, Istanbul, Turkey.
  • Yazicilar E; Hamidiye International School of Medicine, University of Health Sciences, Istanbul, Turkey.
  • Pourali M; Hamidiye International School of Medicine, University of Health Sciences, Istanbul, Turkey.
  • Akyokus FE; Hamidiye International School of Medicine, University of Health Sciences, Istanbul, Turkey.
  • Sager SG; Clinics of Pediatric Neurology, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey.
  • Cag Y; Department of Pediatrics, University of Health Sciences Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.
Am J Med Genet A ; : e63855, 2024 Aug 21.
Article en En | MEDLINE | ID: mdl-39166479
ABSTRACT
FCH domain only 1 (FCHO1) is a key player in clathrin-mediated endocytosis, vital for various cellular processes, including immune regulation and cancer progression. However, the clinical implications of FCHO1 mutations, particularly in combined immunodeficiency, remain unclear. This systematic review aims to provide an objective analysis of the molecular genetics, clinical manifestations, and potential therapeutic targets associated with FCHO1 mutations. A systematic search following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted across electronic databases up to March 25, 2024, to identify studies investigating the relationship between FCHO1 and different clinical manifestations. Eligibility criteria were applied to screen studies, and data extraction included study characteristics, reported symptoms, genetic variants, and primary outcomes. In silico analyses were performed to assess protein-protein interactions and gene expression patterns. Five studies were included, offering insights into the molecular genetics, T-cell deficiency mechanisms, clinical manifestations, and potential therapeutic targets associated with FCHO1 mutations. Molecular analyses identified specific mutations disrupting FCHO1 function, leading to impaired T-cell proliferation, cytokine production, and susceptibility to infections. Clinically, patients exhibited recurrent infections, lymphopenia, and malignancies, with allogeneic hematopoietic stem cell transplantation emerging as a therapeutic option. In silico analyses revealed potential interactions and co-expression between FCHO1 and genes involved in cancer progression and immune signaling pathways. This systematic review objectively elucidates the multifaceted role of FCHO1 in immune regulation and disease pathogenesis. Understanding the molecular mechanisms underlying FCHO1 mutations and their impact on disease manifestations is crucial for guiding clinical management and developing targeted therapeutic strategies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Med Genet A Asunto de la revista: GENETICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Med Genet A Asunto de la revista: GENETICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Estados Unidos